A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers

Phase 1

Pfizer